Agilent Posts 19 Percent Jump in Q1 Life Sciences Revenues Driven by LC, Mass Spec Sales

The increase in sales was driven significantly by an acceleration in the instrument replacement cycle, particularly in the case of large pharmaceutical companies, said a company official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.